Compare $MLYS vs $VRDN | Chartloom

Compare

$MLYS vs $VRDN

Mineralys Therapeutics Inc · Viridian Therapeutics Inc

MLYS

Mineralys Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Compare $MLYS vs $VRDN

Comparing Mineralys Therapeutics Inc and Viridian Therapeutics Inc

MLYSMineralys Therapeutics Inc

VRDNViridian Therapeutics Inc

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MLYS

VRDN

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Market Cap

MLYS$2.06B

VRDN$2.06B

Enterprise Value

MLYS$2.02B

VRDN$2.25B

Price

MLYS$23.37

VRDN$18.66

P/E Ratio

MLYSN/A

VRDNN/A

P/S Ratio

MLYS0.00x

VRDN28.97x

EV/Sales

MLYS0.00x

VRDN31.65x

EV/EBITDA

MLYS0.00x

VRDN0.00x

P/B Ratio

MLYS3.79x

VRDN3.58x

P/FCF Ratio

MLYSN/A

VRDNN/A

EV/FCF

MLYS-5.96x

VRDN-6.72x

PEG Ratio

MLYSN/A

VRDNN/A

Forward P/E (NTM)

MLYSN/A

VRDNN/A

Forward P/S (NTM)

MLYS30.20x

VRDN14.59x

Revenue (TTM)

MLYS$0

VRDN$71M

Revenue Growth (YoY)

MLYSN/A

VRDN23220.3%

Forward Rev Growth

MLYS106.7%

VRDN729.0%

Gross Margin (TTM)

MLYS0.0%

VRDN2.4%

Operating Margin (TTM)

MLYS0.0%

VRDN0.0%

EBITDA Margin (TTM)

MLYS0.0%

VRDN-569.0%

Net Margin (TTM)

MLYS0.0%

VRDN-544.1%

FCF Margin (TTM)

MLYSN/A

VRDN-471.0%

Net Income (TTM)

MLYS$-350M

VRDN$-387M

FCF (TTM)

MLYS$-339M

VRDN$-335M

EPS (TTM)

MLYS-$4.13

VRDN-$3.59

ROE (TTM)

MLYS-5797.0%

VRDN-6135.0%

ROA (TTM)

MLYS-5415.0%

VRDN-4603.0%

ROIC (TTM)

MLYS-5571.0%

VRDN-5041.0%

Cash

MLYS$138M

VRDN$165M

Debt

MLYS$98M

VRDN$356M

Net Cash/Debt

MLYS$41M

VRDN$-191M

Current Ratio (TTM)

MLYS34.46x

VRDN16.95x

Quick Ratio (TTM)

MLYS34.24x

VRDN16.56x

Debt/Equity (TTM)

MLYS0.18x

VRDN0.54x

Debt/Assets (TTM)

MLYS0.0%

VRDN0.0%

Interest Coverage (TTM)

MLYSN/A

VRDNN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

VRDN0.00x

Beta

MLYS0.64

VRDN1.11

52W Performance

MLYS-37.7%

VRDN-12.6%

YTD Performance

MLYS-34.6%

VRDN-39.2%

% from 52W High

MLYS-51.0%

VRDN-45.6%

% from 52W Low

MLYS8.9%

VRDN41.6%

Asset Turnover (TTM)

MLYS0.00x

VRDN0.08x

FCF Yield (TTM)

MLYS-16.5%

VRDN-16.3%

Earnings Yield (TTM)

MLYS-17.0%

VRDN-18.8%

Dividend Yield (TTM)

MLYSN/A

VRDNN/A

Rule of 40

MLYS0.0

VRDN22,749.3

EV/GP/RG

MLYSN/A

VRDN8.67

Ticker research

View MLYS research View VRDN research

Metric	MLYS Mineralys Therapeutics Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.06B	$2.06B
Enterprise Value	$2.02B	$2.25B
Price	$23.37	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	28.97x
EV/Sales	0.00x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	N/A	23220.3%
Forward Rev Growth	106.7%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-350M	$-387M
FCF (TTM)	$-339M	$-335M
EPS (TTM)	-$4.13	-$3.59
ROE (TTM)	-5797.0%	-6135.0%
ROA (TTM)	-5415.0%	-4603.0%
ROIC (TTM)	-5571.0%	-5041.0%
Financial Health
Cash	$138M	$165M
Debt	$98M	$356M
Net Cash/Debt	$41M	$-191M
Current Ratio (TTM)	34.46x	16.95x
Quick Ratio (TTM)	34.24x	16.56x
Debt/Equity (TTM)	0.18x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	1.11
52W Performance	-37.7%	-12.6%
YTD Performance	-34.6%	-39.2%
% from 52W High	-51.0%	-45.6%
% from 52W Low	8.9%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-16.5%	-16.3%
Earnings Yield (TTM)	-17.0%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View MLYS research	View VRDN research

Valuation

P/S Ratio

MLYS

0.00x

VRDN

28.97x

EV/FCF

VRDN

-6.72x

MLYS

-5.96x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

Forward Revenue Growth

VRDN

729.0%

MLYS

106.7%

Profitability & performance

Gross Margin

VRDN

2.4%

MLYS

0.0%

ROE

MLYS

-5797.0%

VRDN

-6135.0%

FCF Yield %

VRDN

-16.3%

MLYS

-16.5%

52-Week Performance

VRDN

-12.6%

MLYS

-37.7%

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Market Cap

MLYS$2.06B

VRDN$2.06B

Enterprise Value

MLYS$2.02B

VRDN$2.25B

Price

MLYS$23.37

VRDN$18.66

P/E Ratio

MLYSN/A

VRDNN/A

P/S Ratio

MLYS0.00x

VRDN28.97x

EV/Sales

MLYS0.00x

VRDN31.65x

EV/EBITDA

MLYS0.00x

VRDN0.00x

P/B Ratio

MLYS3.79x

VRDN3.58x

P/FCF Ratio

MLYSN/A

VRDNN/A

EV/FCF

MLYS-5.96x

VRDN-6.72x

PEG Ratio

MLYSN/A

VRDNN/A

Forward P/E (NTM)

MLYSN/A

VRDNN/A

Forward P/S (NTM)

MLYS30.20x

VRDN14.59x

Revenue (TTM)

MLYS$0

VRDN$71M

Revenue Growth (YoY)

MLYSN/A

VRDN23220.3%

Forward Rev Growth

MLYS106.7%

VRDN729.0%

Gross Margin (TTM)

MLYS0.0%

VRDN2.4%

Operating Margin (TTM)

MLYS0.0%

VRDN0.0%

EBITDA Margin (TTM)

MLYS0.0%

VRDN-569.0%

Net Margin (TTM)

MLYS0.0%

VRDN-544.1%

FCF Margin (TTM)

MLYSN/A

VRDN-471.0%

Net Income (TTM)

MLYS$-350M

VRDN$-387M

FCF (TTM)

MLYS$-339M

VRDN$-335M

EPS (TTM)

MLYS-$4.13

VRDN-$3.59

ROE (TTM)

MLYS-5797.0%

VRDN-6135.0%

ROA (TTM)

MLYS-5415.0%

VRDN-4603.0%

ROIC (TTM)

MLYS-5571.0%

VRDN-5041.0%

Cash

MLYS$138M

VRDN$165M

Debt

MLYS$98M

VRDN$356M

Net Cash/Debt

MLYS$41M

VRDN$-191M

Current Ratio (TTM)

MLYS34.46x

VRDN16.95x

Quick Ratio (TTM)

MLYS34.24x

VRDN16.56x

Debt/Equity (TTM)

MLYS0.18x

VRDN0.54x

Debt/Assets (TTM)

MLYS0.0%

VRDN0.0%

Interest Coverage (TTM)

MLYSN/A

VRDNN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

VRDN0.00x

Beta

MLYS0.64

VRDN1.11

52W Performance

MLYS-37.7%

VRDN-12.6%

YTD Performance

MLYS-34.6%

VRDN-39.2%

% from 52W High

MLYS-51.0%

VRDN-45.6%

% from 52W Low

MLYS8.9%

VRDN41.6%

Asset Turnover (TTM)

MLYS0.00x

VRDN0.08x

FCF Yield (TTM)

MLYS-16.5%

VRDN-16.3%

Earnings Yield (TTM)

MLYS-17.0%

VRDN-18.8%

Dividend Yield (TTM)

MLYSN/A

VRDNN/A

Rule of 40

MLYS0.0

VRDN22,749.3

EV/GP/RG

MLYSN/A

VRDN8.67

Ticker research

View MLYS research View VRDN research

Metric	MLYS Mineralys Therapeutics Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.06B	$2.06B
Enterprise Value	$2.02B	$2.25B
Price	$23.37	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	28.97x
EV/Sales	0.00x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	N/A	23220.3%
Forward Rev Growth	106.7%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-350M	$-387M
FCF (TTM)	$-339M	$-335M
EPS (TTM)	-$4.13	-$3.59
ROE (TTM)	-5797.0%	-6135.0%
ROA (TTM)	-5415.0%	-4603.0%
ROIC (TTM)	-5571.0%	-5041.0%
Financial Health
Cash	$138M	$165M
Debt	$98M	$356M
Net Cash/Debt	$41M	$-191M
Current Ratio (TTM)	34.46x	16.95x
Quick Ratio (TTM)	34.24x	16.56x
Debt/Equity (TTM)	0.18x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	1.11
52W Performance	-37.7%	-12.6%
YTD Performance	-34.6%	-39.2%
% from 52W High	-51.0%	-45.6%
% from 52W Low	8.9%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-16.5%	-16.3%
Earnings Yield (TTM)	-17.0%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View MLYS research	View VRDN research